Schoretsanitis, Georgios and Paulzen, Michael and Unterecker, Stefan and Schwarz, Markus and Conca, Andreas and Zernig, Gerald and Gruender, Gerhard and Haen, Ekkehard and Baumann, Pierre and Bergemann, Niels and Clement, Hans Willi and Domschke, Katharina and Eckermann, Gabriel and Egberts, Karin and Gerlach, Manfred and Greiner, Christine and Havemann-Reinecke, Ursula and Hefner, Gudrun and Helmer, Renate and Janssen, Ger and Jaquenoud-Sirot, Eveline and Laux, Gerd and Messer, Thomas and Moessner, Rainald and Mueller, Matthias J. and Pfuhlmann, Bruno and Riederer, Peter and Saria, Alois and Schoppek, Bernd and Silva Gracia, Margarete and Stegmann, Benedikt and Steimer, Werner and Stingl, Julia C. and Uhr, Manfred and Ulrich, Sven and Waschgler, Roland and Zurek, Gabriela and Hiemke, Christoph (2018) TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 19 (3). pp. 162-174. ISSN 1562-2975, 1814-1412
Full text not available from this repository. (Request a copy)Abstract
Objectives: Therapeutic drug monitoring (TDM) combines the quantification of drug concentrations in blood, pharmacological interpretation and treatment guidance. TDM introduces a precision medicine tool in times of increasing awareness of the need for personalized treatment. In neurology and psychiatry, TDM can guide pharmacotherapy for patient subgroups such as children, adolescents, pregnant women, elderly patients, patients with intellectual disabilities, patients with substance use disorders, individuals with pharmacokinetic peculiarities and forensic patients. Clear indications for TDM include lack of clinical response in the therapeutic dose range, assessment of drug adherence, tolerability issues and drug-drug interactions.Methods: Based upon existing literature, recommended therapeutic reference ranges, laboratory alert levels, and levels of recommendation to use TDM for dosage optimization without specific indications, conversion factors, factors for calculation of dose-related drug concentrations and metabolite-to-parent ratios were calculated.Results: This summary of the updated consensus guidelines by the TDM task force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie offers the practical and theoretical knowledge for the integration of TDM as part of pharmacotherapy with neuropsychiatric agents into clinical routine.Conclusions: The present guidelines for TDM application for neuropsychiatric agents aim to assist clinicians in enhancing safety and efficacy of treatment.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PHARMACOKINETICS; SCHIZOPHRENIA; RISPERIDONE; Therapeutic drug monitoring; pharmacokinetics; neuropsychopharmacology; drug therapy; pharmacovigilance |
| Subjects: | 600 Technology > 610 Medical sciences Medicine 600 Technology > 615 Pharmacy |
| Divisions: | Medicine > Lehrstuhl für Psychiatrie und Psychotherapie Chemistry and Pharmacy > Institute of Pharmacy |
| Depositing User: | Petra Gürster |
| Date Deposited: | 17 Jul 2020 09:22 |
| Last Modified: | 17 Jul 2020 09:22 |
| URI: | https://pred.uni-regensburg.de/id/eprint/15296 |
Actions (login required)
 |
View Item |
